New Horizons in Antiretroviral Drug Delivery Systems for HIV Management

被引:0
|
作者
dos Santos, Kayque Almeida [1 ,2 ]
Moreira, Livia Maria Coelho de Carvalho [1 ,3 ]
Soares-Sobrinho, Jose Lamartine [1 ,3 ]
Soares, Monica Felts de La Roca [1 ,3 ]
机构
[1] Univ Fed Pernambuco, Ctr Qual Control Med & Related Prod, Recife, PE, Brazil
[2] Univ Fed Pernambuco, Program Sci Innovat, Recife, PE, Brazil
[3] Univ Fed Pernambuco, Program Pharmaceut Sci, Recife, PE, Brazil
关键词
HIV; antiretroviral treatment; drug delivery systems; controlled drug release; pharmaceutical technology; biopharmaceutical classification system; AMORPHOUS SOLID DISPERSIONS; IN-VITRO; CARBOSILANE DENDRIMERS; IMPROVED DISSOLUTION; ENHANCED SOLUBILITY; EFAVIRENZ; BIOAVAILABILITY; RITONAVIR; DESIGN; CLASSIFICATION;
D O I
10.2174/0109298673306606240802111136
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction Human Immunodeficiency Virus (HIV) infection is still a major global problem, whose drug treatment consists of prophylactic prevention and antiretroviral combination therapy for better pharmacological efficacy and control of the circulating virus. However, there are still pharmacological problems that need to be overcome, such as low aqueous solubility of drugs, toxicity, and low patient adherence. Drug delivery technologies can be used to overcome these barriers.Objective This review summarized the latest drug delivery systems for HIV treatment. Initially, an overview of the current therapy was presented, along with the problems it presents. Then, the latest drug delivery systems used to overcome the challenges imposed in conventional HIV therapy were discussed.Conclusion This review examines innovative approaches for HIV treatment, where various drug delivery systems have shown significant advantages, such as high drug encapsulation, improved solubility, and enhanced bioavailability both in vitro and in vivo. Strategies like cyclodextrins, solid dispersions, microneedles, and nanoparticles are explored to address challenges in drug solubility, bioavailability, and administration routes. Despite progress, obstacles like limited clinical trials and industrial scalability hinder the widespread adoption of these formulations, emphasizing the need for further research and collaboration to optimize and ensure accessibility of innovative HIV therapies, mainly in regions where access to HIV treatment is scarce and remains a challenge.
引用
收藏
页数:33
相关论文
共 50 条